Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00403325
Status:
COMPLETED
Last Update Posted:
2008-11-02
First Post:
2006-11-22
Brief Title:
Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy
Sponsor:
Vitreous -Retina- Macula Consultants of New York
Organization:
Vitreous -Retina- Macula Consultants of New York
Study Overview
Official Title:
Phase I Study of Intravitreally Administered Ranibizumab in Subjects With Unresolving CSC and Subfoveal Fluid
Status:
COMPLETED
Status Verified Date:
2008-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to examine the effects of Lucentis for active Central Serous Chorioretinopathy
Detailed Description:
This is an open-label Phase I study of intravitreally administered ranibizumab in subjects with unresolving CSC and subfoveal fluid Patients will be evaluated at baseline with ophthalmic examination fluorescein angiography optical coherence tomography and color photography Subjects will receive open-label intravitreal injections of 05 mg ranibizumab administered every 28 days 2 days for 3 injections Thereafter they are to be evaluated every month until month 12 Treatment will be administered to patients if there is presence of active leakage as determined by fluorescein angiography or persistence presence of sub retinal fluid upon OCT examination at that monthly visit
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None